New drug combo takes on tough pancreatic cancer

NCT ID NCT03854110

Recruiting now Disease control Sponsor: Persevere Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This early-phase trial tests a new drug called GP-2250 combined with the chemotherapy gemcitabine in people with advanced pancreatic cancer that has worsened after standard treatment. The main goal is to check safety and find the right dose. About 64 adults will take part, and researchers will also look for signs that the cancer is shrinking or slowing down.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GP-2250 (a new drug) combined with gemcitabine (standard chemotherapy)
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a very early Phase 1 trial with only 64 people, focused on safety and dosing. It is too soon to know if the combination will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm ovarian cancer ovarian carcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER PANCREATIC CANCER, ADULT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Abramson Cancer Center at the University of Pennsylvania
RECRUITING

Phildelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Rush University Medical Center
RECRUITING

Chicago, Illinois, 60607, United States

Contact Phone: •••-•••-••••
University of Kansas Cancer Center
RECRUITING

Fairway, Kansas, 66205, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.